$25.65
-2.04 (-7.37%)
Open$27.86
Previous Close$27.69
Day High$27.86
Day Low$25.64
52W High$54.29
52W Low$9.00
Volume—
Avg Volume26.0K
Market Cap92.91M
P/E Ratio—
EPS$-20.71
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+6.4% upside
Current
$25.65
$25.65
Target
$27.28
$27.28
$18.57
$27.28 avg
$35.01
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 32.35M | 12.22M | 12.16M |
| Net Income | -83,445,626 | 1.67M | 1.59M |
| Profit Margin | -257.9% | 13.7% | 13.1% |
| EBITDA | -60,012,213 | 2.79M | 3.00M |
| Free Cash Flow | — | 1.30M | 1.27M |
| Rev Growth | — | +12.4% | +20.7% |
| Debt/Equity | — | 0.63 | 0.63 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |